Parexel eyes Dublin for new hub; India goes to bat for GVK;

> Parexel International ($PRXL) is plotting a new corporate hub in Dublin, adding up to 130 positions to staff the operation. News

> India is putting off trade discussions with the European Union in response to the continent's ban of more than 700 drugs with ties to the data scandal at Indian CRO GVK BioSciences. Story

> PRA Health Sciences ($PRAH) is expanding its eClinical operation with a $2.5 million deal for Value Health Solutions. Item

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.